U.S. IPO market shows weakness as MiniMed stumbles The diabetes medtech sector faced headwinds this week as MiniMed Group's IPO debut resulted in an 8 percent decline, marking a challenging start for the newly public company. The offering was the sole traditional IPO to reach the market during an otherwise quiet period for capital raises. Two SPAC transactions also closed, providing limited alternative pathways for companies seeking public market access. Adding to the sluggish momentum, just one small issuer joined the IPO pipeline, signaling continued caution among companies considering going public. The weak performance underscores persistent investor hesitation in the medtech space and broader IPO market softness. Market conditions remain constrained as companies weigh the costs and benefits of public offerings amid ongoing economic uncertainty and volatile equity valuations.